| Indication | Oncology |
| Status | ‒ ODD for treatment of chronic myeloid leukemia on March 17th, 2022. ‒ NDA receipt on September 23th, 2022. ‒ ODD for treatment of acute lymphoblastic leukemia on November 3rd, 2022. ‒ CRL on April 27th, 2023. Handa will supplement deficiencies and submit to FDA ASAP. |
| Product Advantages | Handa is utilizing its ONCORE™ technology to develop improved versions of Oncology drug for reducing the risk associated with sever side effect.。 |
| Potential Market | According to the data in 2021 annual report of the brand company, the total sales of the brand drug were US$2.117 billion (US$1.297 billion in the U.S. and US$820 million rest of world). |
?
R&D
HND-033
